The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion

References

• Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 2013;19:411–419.
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–955.
   PubMed Web of Science ®Google Scholar
• Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg. 2005;92:1393–1398.
   PubMed Web of Science ®Google Scholar
• Choi D, Lim HK, Rhim H ,et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007;14:2319–2329.
   PubMed Web of Science ®Google Scholar
• Song KD, Lim HK, Rhim H, et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. Radiology. 2015;275:599–608.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012;262:689–700.
   PubMed Web of Science ®Google Scholar
• Tan L, Chen S, Wei G, et al. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett. 2019;460:29–40.
   PubMed Web of Science ®Google Scholar
• Su T, Liao J, Dai Z, et al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018;37:3514–3527.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58:1667–1680.
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–855.
   PubMed Web of Science ®Google Scholar
• Hou YF, Li B, Wei YG et al. Second hepatectomy improves survival in patients with microvascular invasive hepatocellular carcinoma meeting the Milan criteria. Medicine. 2015;94:e2070.
   PubMed Web of Science ®Google Scholar
• Meniconi RL, Komatsu S, Perdigao F, et al. Recurrent hepatocellular carcinoma: a western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015;157:454–462
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24:2074–2081.
   PubMed Web of Science ®Google Scholar
• Ren ZG, Lin ZY, Xia JL, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol. 2004;10:2791–2794.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang B, Yin X, et al. Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2013;139:773–781.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–1391.e1386.
   PubMed Web of Science ®Google Scholar
• Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology. 1996;43:1405–1409.
   PubMed Web of Science ®Google Scholar
• Chua TC, Saxena A, Chu F, et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol. 2011;16:125–132.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33;550–558.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–432.
   PubMed Web of Science ®Google Scholar
• Shao G, Zou Y, Lucatelli P, et al. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med. 2021;9(8):714.
   PubMed Web of Science ®Google Scholar
• Lucatelli P, Burrel M, Guiu B, et al. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851–1867.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301(3):533–540.
   PubMed Web of Science ®Google Scholar
• Chen S, Peng Z, Lin M, et al. Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1-5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. Eur Radiol. 2018;28:3651–3660.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273:241–260.
   PubMed Web of Science ®Google Scholar
• Sacks D, McClenny TE, Cardella JF, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–S202.
   PubMed Web of Science ®Google Scholar
• Leoni CJ, Potter JE, Rosen MP, et al. Classifying complications of interventional procedures: a survey of practicing radiologists. J Vasc Interv Radiol. 2001;12(1):55–59.
   PubMed Web of Science ®Google Scholar
• Shi M, Zhang CQ, Zhang YQ, et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg. 2004;28:376–381.
   PubMed Web of Science ®Google Scholar
• Yamashiki N, Yoshida H, Tateishi R, et al. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J Gastroenterol Hepatol. 2007;22:2155–2160.
   PubMed Web of Science ®Google Scholar